Drug Trial Radar · NCT06716606
A Study to Investigate the Long-term Safety and Efficacy of Belimumab in Adults With Interstitial Lung Disease (ILD) Associated With Systemic Sclerosis (SSc) and Other Connective Tissue Diseases (CTD) (BLISSconneCTD-OLE)
Last checked: Nov 20, 2026Latest source record: Sep 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
514
Planned (sponsor's estimate)
Start
Dec 12, 2024
Primary completion
Sep 27, 2030
Study completion Oct 23, 2030
Sponsor
- Lead sponsor
- GlaxoSmithKlineGSK (GSK)
- Sponsor type
- Industry
- Collaborators
- ICON plc
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open label extension (OLE) study of an ongoing randomized controlled parent clinical studies 218224 (NCT05878717) and 221672 (NCT06572384) which aim to assess the efficacy and safety of belimumab on reducing the decline in lung function in participants with interstitial lung disease associated with diffuse cutaneous systemic sclerosis (dcSSc-ILD) and interstitial lung disease associated with other connective tissue diseases (CTD-ILD), respectively. The OLE study will describe how well tolerated belimumab will be long term, and whether it might continue to slow progression of lung function decline, slow overall disease progression and improve quality of life.
Conditions
- Connective Tissue Diseases
Interventions
BelimumabDrug
Belimumab will be administered.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of participants with Adverse events (AEs), Adverse Event of Special Interest events (AESIs), and Serious Adverse Event (SAEs)Time frame: Up to approximately 5 years
Locations
41 sites in 11 countries. Site status is shown where the registry gives one.
GSK Investigational Site
Los Angeles, California · Recruiting
GSK Investigational Site
New York, New York · Recruiting
GSK Investigational Site
Philadelphia, Pennsylvania · Recruiting
GSK Investigational Site
Philadelphia, Pennsylvania · Recruiting
GSK Investigational Site
Buenos Aires, Argentina · Recruiting
GSK Investigational Site
Buenos Aires, Argentina · Recruiting
GSK Investigational Site
Ciudad Autonoma Buenos Aires, Argentina · Recruiting
GSK Investigational Site
Ciudad Autonoma de Buenos Aire, Argentina · Recruiting
GSK Investigational Site
Santa Fe, Argentina · Recruiting
GSK Investigational Site
Fitzroy, Victoria, Australia · Recruiting
GSK Investigational Site
Beijing, China · Recruiting
GSK Investigational Site
Beijing, China · Recruiting
GSK Investigational Site
Chengdu, China · Recruiting
GSK Investigational Site
Hangzhou, China · Recruiting
GSK Investigational Site
Mianyang, China · Recruiting
GSK Investigational Site
Shanghai, China · Recruiting
GSK Investigational Site
Shanghai, China · Recruiting
GSK Investigational Site
Shenyang, China · Recruiting
GSK Investigational Site
Zhuzhou, China · Recruiting
GSK Investigational Site
Toulouse, France · Recruiting
GSK Investigational Site
Larissa, Greece · Recruiting
GSK Investigational Site
Thessaloniki, Greece · Recruiting
GSK Investigational Site
Poria – Neve Oved, Israel, Israel · Recruiting
GSK Investigational Site
Aichi, Japan · Recruiting
GSK Investigational Site
Gunma, Japan · Recruiting
GSK Investigational Site
Hiroshima, Japan · Recruiting
GSK Investigational Site
Hokkaido, Japan · Recruiting
GSK Investigational Site
Tokushima, Japan · Recruiting
GSK Investigational Site
Tokyo, Japan · Recruiting
GSK Investigational Site
Tokyo, Japan · Recruiting
GSK Investigational Site
Tokyo, Japan · Recruiting
GSK Investigational Site
Yamanashi, Japan · Recruiting
GSK Investigational Site
Bucheon Kyunggi-Do, South Korea · Recruiting
GSK Investigational Site
Seoul, South Korea · Recruiting
GSK Investigational Site
Suwon Kyunggi-do, South Korea · Recruiting
GSK Investigational Site
Yongsan-Ku Seoul, South Korea · Recruiting
GSK Investigational Site
Barcelona, Spain · Recruiting
GSK Investigational Site
VigoPontevedra, Spain · Recruiting
GSK Investigational Site
Bilbao, Bizkaia, Spain · Recruiting
GSK Investigational Site
Leeds, United Kingdom · Recruiting
Showing 40 of 41 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.